bevacizumab,atezolizumab
roche
['gyn', 'bevacizumab', 'atezo', 'improve ', 'atalante', 'ovarian', 'immune therap']
atalante presented at oral gyneacological cancer at 2022.
the addition of immune therapy (atezolizumab) to chemo combined with bevacizumab does not improve progression free survival in sensitive relapse ovarian cancer. #oncology #cancer #research #clinicaltrials #esmo 
Arcagy-Gineco : a non-profit independant research group at the heart of gynecologic cancer research and information